Location of Repository

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

By F H Blackhall, M Ranson, J A Radford, B W Hancock, M Soukop, A T McGown, A Robbins and G Halbert


Bryostatin 1 is a naturally occurring macrocyclic lactone with promising antitumour and immunomodulatory function in preclinical and phase I clinical investigations. In this phase II study, 17 patients with progressive non-Hodgkin's lymphoma of indolent type (NHL), previously treated with chemotherapy, received a median of 6 (range 1–9) intravenous infusions of 25 μg/m2bryostatin 1 given once weekly over 24 hours. In 14 evaluable patients no responses were seen. Stable disease was attained in one patient for 9 months. The principal toxicities were myalgia and phlebitis. Treatment was discontinued early because of toxicity alone (phlebitis) in 2 patients, toxicity in addition to progressive disease in 3 patients (myalgia and phlebitis n = 2; thrombocytopenia n = 1) and progressive disease in 5 patients. The results fail to demonstrate efficacy of this regimen of bryostatin 1 in the treatment of NHL. In light of preclinical data that demonstrate synergy between bryostatin 1 and several cytotoxic agents and cytokines, clinical studies to investigate bryostatin 1 in combination are warranted. We also present data to demonstrate that central venous lines may be used in future studies to avoid phlebitis. © 2001 Cancer Research Campaign http://www.bjcancer.co

Topics: Regular Article
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2363763
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • http://www.bjcancer.com (external link)
  • Suggested articles



    1. (1999). A Phase I trial of bryostatin 1 in children with refractory solid tumours: a Pediatric Oncology Group study.
    2. (1998). Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 4: 1305–1314 Basu A and Lazo JS
    3. (1995). Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study.
    4. (1993). Chem soc 104: 6846–6848
    5. (1998). High Performance liquid chromatographic assay for the novel antitumour drug, bryostatin-1, incorporating a serum extraction technique.
    6. (1994). Immunomodulation in patients receiving intravenous bryostatin 1 in a phase 1 clinical study: comparison with effects of bryostatin 1 on lymphocyte function in vitro. Cancer Immunol Immunother 39: 223–230 Sharkis SJ,
    7. (1997). Res 5(9): 2344–2348 Wojtowicz-Praga SM,
    8. (1994). Successful treatment of human Waldenstrom’s macroglobulinaemia with combination biological and chemotherapy agents.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.